Review
Published on 23 Jan 2023
Sulforaphane: An emergent anti-cancer stem cell agent
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1089115
- 20,757 views
- 14 citations
Type at least 3 characters
1,724 articles
Articles
Original Research
Published on 20 Jan 2023
HROP68: A rare case of medullary pancreatic cancer—characterization and chemosensitivity of the first patient-derived cell line
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1082927
- 1,997 views
- 2 citations
Original Research
Published on 20 Jan 2023
14-3-3 and Smad2/3 are crucial mediators of atypical-PKCs: Implications for neuroblastoma progression
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1051516
- 2,047 views
Review
Published on 19 Jan 2023
The role of miR-128 in cancer development, prevention, drug resistance, and immunotherapy
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1067974
- 3,324 views
- 22 citations
Mini Review
Published on 19 Jan 2023
Patient-derived models: Advanced tools for precision medicine in neuroblastoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1085270
- 4,103 views
- 5 citations
Original Research
Published on 18 Jan 2023
The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.966441
- 3,672 views
- 12 citations
Original Research
Published on 16 Jan 2023
FOXO3 gene hypermethylation and its marked downregulation in breast cancer cases: A study on female patients
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1078051
- 2,609 views
- 3 citations
Review
Published on 13 Jan 2023
Crosstalk between microwave ablation and ferroptosis: The next hot topic?
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1099731
- 2,793 views
- 6 citations
Original Research
Published on 13 Jan 2023
Evaluating the local expression pattern of IGF-1R in tumor tissues and the circulating levels of IGF-1, IGFBP-1, and IGFBP-3 in the blood of patients with different primary bone tumors
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1096438
- 2,075 views
- 3 citations
Case Report
Published on 12 Jan 2023
Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1064944
- 1,367 views
Original Research
Published on 12 Jan 2023
Development of anoikis-related genes signature to predict the prognosis in gastric cancer patients
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1096608
- 3,614 views
- 10 citations
Case Report
Published on 10 Jan 2023
Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1031396
- 1,582 views
Brief Research Report
Published on 10 Jan 2023
Mild oxidative stress protects against chemotherapy-induced hair loss
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1078916
- 1,978 views
- 1 citation
Review
Published on 10 Jan 2023
Potassium channels: Novel targets for tumor diagnosis and chemoresistance
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1074469
- 4,392 views
- 14 citations
Review
Published on 09 Jan 2023
CircCCDC66: Emerging roles and potential clinical values in malignant tumors
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1061007
- 2,888 views
- 4 citations
Correction
Published on 06 Jan 2023
Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1124912
- 1,025 views